TY - JOUR
T1 - Frequency and topography of cerebral microbleeds in dementia with Lewy bodies compared to Alzheimer's disease
AU - Gungor, Ipek
AU - Sarro, Lidia
AU - Graff-Radford, Jonathan
AU - Zuk, Samantha M.
AU - Tosakulwong, Nirubol
AU - Przybelski, Scott A.
AU - Lesnick, Tim
AU - Boeve, Bradley F.
AU - Ferman, Tanis J.
AU - Smith, Glenn E.
AU - Knopman, David S.
AU - Filippi, Massimo
AU - Petersen, Ronald C.
AU - Jack, Clifford R.
AU - Kantarci, Kejal
N1 - Funding Information:
Dr. Petersen serves on scientific advisory boards for Elan Pharmaceuticals, Wyeth Pharmaceuticals, and GE Healthcare and receives research support from the NIH ( P50-AG16574 [PI] and U01-AG06786 [PI], R01-AG11378 [Co-I], and U01–24904 [Co-I]).
Funding Information:
Dr. Boeve has served as an investigator for a clinical trial sponsored by GE Healthcare. He receives royalties from the publication of a book entitled Behavioral Neurology Of Dementia (Cambridge Medicine, 2009). He serves on the Scientific Advisory Board of the Tau Consortium. He receives research support from the NIH ( U01 AG045390 , U54 NS092089 , P50 AG016574 , UO1 AG006786 , RO1 AG015866 , RO1 AG032306 , RO1 AG041797 ), and the Mangurian Foundation for Lewy body research.
Funding Information:
Funding : Financial support for the conduct of the research was provided by the NIH ( R01 AG040042 , P50 AG016574 , R01 AG11378 ) the Mangurian Foundation for Lewy body research, and the Robert H. and Clarice Smith and Abigail Van Buren Alzheimer s Disease Research Program. Sponsors did not have any role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.
Funding Information:
Dr. Kantarci serves on the data safety monitoring board for Pfizer Inc and Johnson Alzheimer Immunotherapy; serves on the data safety monitoring board for Takeda Global Research & Development Center, Inc; and she is funded by the NIH ( R01AG040042 , P50 AG44170 , P50 AG16574 , U19 AG10483 , U01 AG042791 ) and Minnesota Partnership for Biotechnology and Medical Genomics ( PO03590201 ).
Funding Information:
Dr. Knopman serves as Deputy Editor for Neurology ® ; serves on a Data Safety Monitoring Board for Lundbeck Pharmaceuticals and for the Dominantly Inherited Alzheimer's Disease Treatment Unit. He is participating in clinical trials sponsored by Lilly Pharmaceuticals and TauRx Pharmaceuticals. He receives research support from the NIH.
Funding Information:
Dr. Jack serves as a consultant for Eli Lilly. He receives research funding from the National Institutes of Health ( R01-AG011378 , RO1-AG037551 , U01-HL096917 , U01-AG032438 , U01-AG024904 ), and the Alexander Family Alzheimer's Disease Research Professorship of the Mayo Foundation Family.
Publisher Copyright:
© 2015 The Authors.
PY - 2015/9/1
Y1 - 2015/9/1
N2 - Aim: To determine the frequency and topographic distribution of cerebral microbleeds (CMBs) in dementia with Lewy bodies (DLB) in comparison to CMBs in Alzheimer disease dementia (AD). Methods: Consecutive probable DLB (n = 23) patients who underwent 3-T T2* weighted gradient-recalled-echo MRI, and age and gender matched probable Alzheimer's disease patients (n = 46) were compared for the frequency and location of CMBs. Results: The frequency of one or more CMBs was similar among patients with DLB (30%) and AD (24%). Highest densities of CMBs were found in the occipital lobes of patients with both DLB and AD. Patients with AD had greater densities of CMBs in the parietal, temporal lobes and infratentorial regions compared to DLB (p < 0.05). Conclusion: CMBs are as common in patients with DLB as in patients with AD, with highest densities observed in the occipital lobes, suggesting common pathophysiologic mechanisms underlying CMBs in both diseases.
AB - Aim: To determine the frequency and topographic distribution of cerebral microbleeds (CMBs) in dementia with Lewy bodies (DLB) in comparison to CMBs in Alzheimer disease dementia (AD). Methods: Consecutive probable DLB (n = 23) patients who underwent 3-T T2* weighted gradient-recalled-echo MRI, and age and gender matched probable Alzheimer's disease patients (n = 46) were compared for the frequency and location of CMBs. Results: The frequency of one or more CMBs was similar among patients with DLB (30%) and AD (24%). Highest densities of CMBs were found in the occipital lobes of patients with both DLB and AD. Patients with AD had greater densities of CMBs in the parietal, temporal lobes and infratentorial regions compared to DLB (p < 0.05). Conclusion: CMBs are as common in patients with DLB as in patients with AD, with highest densities observed in the occipital lobes, suggesting common pathophysiologic mechanisms underlying CMBs in both diseases.
KW - Alzheimer disease
KW - Cerebral amyloid angiopathy
KW - Cerebral microbleeds
KW - Dementia with Lewy bodies
KW - T2 weighted gradient-recalled-echo MRI
UR - http://www.scopus.com/inward/record.url?scp=84940614770&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84940614770&partnerID=8YFLogxK
U2 - 10.1016/j.parkreldis.2015.07.008
DO - 10.1016/j.parkreldis.2015.07.008
M3 - Article
C2 - 26205074
AN - SCOPUS:84940614770
SN - 1353-8020
VL - 21
SP - 1101
EP - 1104
JO - Parkinsonism and Related Disorders
JF - Parkinsonism and Related Disorders
IS - 9
ER -